Sarcopenic obesity (SO), defined as the coexistence of low muscle mass and function and excessive fat mass, is increasingly recognized as a health concern in older individuals with diabetes. Despite its clinical importance, SO often remains undiagnosed in outpatient settings due to complex diagnostic requirements.
Objective:
This study aimed to investigate the risk of SO using simple screening tools, namely the SARC-F questionnaire and handgrip strength (HGS), and to identify associated clinical, functional, and metabolic factors in diabetic patients aged 50 and older.
Methods:
A cross-sectional analysis was conducted with 276 diabetic outpatients. Risk of SO was defined based on a body mass index of 30 kg/m² or more, combined with either a SARC-F score of 4 or above or low HGS values (below 35 kg for men and 20 kg for women). Data on comorbidities, functionality, falls, depression, and metabolic control were collected.
Results:
The prevalence of SO risk was 16.2% with HGS and 8.7% with SARC-F. Falls, depressive symptoms, and reduced quality of life were associated with SARC-F-based SO, while hypertension, elevated HbA1c, and lower quality of life were linked to HGS-based SO.
Conclusion:
Simple screening methods can help identify SO risk in diabetic outpatients and support timely clinical decision-making.
CigolleCT, LangaKM, KabetoMU, et al.Geriatric conditions and disability: The Health and Retirement Study. Ann Intern Med, 2007; 147(3):156–164.
2.
Cruz-JentoftAJ, BahatG, BauerJ, et al.; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing, 2019; 48(1):16–31.
VeroneseN, PizzolD, DemurtasJ, et al.; Special Interest Groups of Systematic Reviews and Meta-Analysis for Healthy Ageing, Diabetes, Sarcopenia of European Geriatric Medicine Society (EuGMS). Association between sarcopenia and diabetes: A systematic review and meta-analysis of observational studies. Eur Geriatr Med, 2019; 10(5):685–696.
7.
DoniniLM, BusettoL, BischoffSC, et al.Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts, 2022; 15(3):321–335; doi: 10.1159/000521241
8.
van der EndeM, den OudenMEM, SchramMT, et al.Prevalence and associated factors of sarcopenic obesity in the general population: The Lifelines Cohort Study. Clin Nutr, 2023; 42(8):1573–1581; doi: 10.1016/j.clnu.2023.06.018
9.
World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 2013; 310(20):2191–2194; doi: 10.1001/jama.2013.281053
10.
BahatG, YilmazO, OrenMM, et al.Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: Methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. Eur Geriatr Med, 2018; 9(1):23–28.
11.
BahatG, AydinCO, TufanA, et al.Muscle strength cut-off values calculated from the young reference population to evaluate sarcopenia in Turkish population. Aging Clin Exp Res, 2021; 33(10):2879–2882; doi: 10.1007/s40520-021-01785-3
12.
FarmerRE, MathurR, SchmidtAF, et al.Associations between measures of sarcopenic obesity and risk of cardiovascular disease and mortality: A cohort study and Mendelian randomization analysis using the UK Biobank. J Am Heart Assoc, 2019; 8(13):e011638.
13.
AltinkaynakM, OzturkCK, GoksoyY, et al.The prevalence of sarcopenic obesity and its relationship with type 2 diabetes in a nursing home. Eur Rev Med Pharmacol Sci, 2023; 27(7):1–8.
14.
MorleyJE, MalmstromTK, MillerDK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle-aged African Americans. J Nutr Health Aging, 2012; 16(7):601–608.
15.
IzumiM, AkifusaS, GanahaS, et al.Activities of daily living decline is a predictor of lowered coughing ability and correlates with rehabilitative effect of tongue cleaning on coughing ability. Odontology, 2019; 107(3):393–400.
16.
ChoCY, AlessiCA, ChoM, et al.The association between chronic illness and functional change among participants in a comprehensive geriatric assessment program. J Am Geriatr Soc, 1998; 46(6):677–682.
17.
KaiserMJ, BauerJM, RamschC, et al.; MNA-International Group. Validation of the Mini Nutritional Assessment short-form (MNA-SF): A practical tool for identification of nutritional status. J Nutr Health Aging, 2009; 13(9):782–788.
18.
LelitoRH, PalumboLO, HanleyM. Psychometric evaluation of a brief geriatric depression screen. Aging Ment Health, 2001; 5(4):387–393.
19.
EuroQol Research Foundation. EQ-5D-5L User Guide: Basic information on how to use the EQ-5D-5L instrument [Internet]. 2019 [cited 2024 Oct 21]. Available from: https://euroqol.org/publications/user-guides
20.
WannametheeSG, AtkinsJL. Muscle loss and obesity: The health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc, 2015; 74(4):405–412.
21.
ChenL-K, WooJ, AssantachaiP, et al.Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc, 2020; 21(3):300–307.e2.
22.
ZhouYY, WangJF, YaoQ, et al.Prevalence of sarcopenic obesity in patients with diabetes and adverse outcomes: A systematic review and meta-analysis. Clin Nutr ESPEN, 2023; 58:128–135; doi: 10.1016/j.clnesp.2023.09.920
23.
EremC, YildizR, KocakM, et al.Prevalence of obesity and associated risk factors in a Turkish population (Trabzon city, Turkey). Obes Res Clin Pract, 2009; 3(2):89–97; doi: 10.1016/j.orcp.2009.01.002
24.
Karvonen-GutierrezCA, KimC. Association of mid-life changes in body size, composition, and obesity status with the menopausal transition. Front Endocrinol (Lausanne), 2022; 13:814872; doi: 10.3389/fendo.2022.814872
25.
BeaudartC, McCloskeyE, BruyèreO, et al.Sarcopenia in daily practice: Assessment and management. BMC Geriatr, 2016; 16(1):170.
26.
ZengY, HuX, XieY, et al.Sarcopenic obesity is associated with frailty among community-dwelling older adults: A cross-sectional study. BMC Geriatr, 2022; 22(1):617; doi: 10.1186/s12877-022-03617-z
27.
ReindersI, MurphyRA, KosterA, et al.Muscle mass and muscle fat infiltration as predictors of incident mobility limitations. J Gerontol A Biol Sci Med Sci, 2016; 71(5):712–718.
28.
HamerM, BattyGD, KivimakiM. Sarcopenic obesity and risk of new onset depressive symptoms in older adults: English Longitudinal Study of Ageing. Int J Obes (Lond), 2015; 39(12):1717–1720; doi: 10.1038/ijo.2015.124
29.
KoYH, LimS, KimJH, et al.The impact of sarcopenia on health-related quality of life in elderly men and women. Korean J Intern Med, 2019; 34(4):877–885; doi: 10.3904/kjim.2018.219
30.
ProkopidisK, GiannosP, ReginsterJY, et al.; Special interest group in Systematic Reviews and Meta-analyses and the Task Force on Pharmaceutical Strategy of the European Geriatric Medicine Society (EuGMS). Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle, 2023; 14(2):671–683; doi: 10.1002/jcsm.13160
31.
MijnarendsDM, ScholsJM, MeijersJM, et al.Burden-of-illness of sarcopenia in community-dwelling older adults. Clin Nutr, 2016; 35(5):1239–1245.
